Therapeutics News and Research

RSS

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.

2 Feb 2010

Researchers identify antiviral small molecule that is effective against numerous viruses

Viruses are insidious creatures. They differ from each other in many ways, and they can mutate - at times seemingly at will, as with HIV - to resist a host of weapons fired at them. Complicating matters further is that new viruses are constantly emerging.

2 Feb 2010

Denim blue jeans ribbon campaign: an initiative to raise awareness about children with rare diseases

Hope – It's In Our Genes.™ The Children's Rare Disease Network (http://www.crdnetwork.org) today announced the Global Genes Project (http://www.globalgenesproject.org), an initiative designed to raise awareness about the prevalence of rare diseases that afflict millions of children worldwide. Rare disease advocates organizing the campaign selected a blue jeans denim ribbon as the international symbol of hope for children suffering from life threatening and chronically debilitating rare diseases.

1 Feb 2010

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.

1 Feb 2010

Enzo Biochem generating more than $100M in revenues annually

Enzo Biochem, Inc. is well positioned to benefit from the results of its transformation involving acquisitions, new managements at each of its major subsidiaries and a heightened focus on new life science, diagnostic and therapeutic products, Barry Weiner, President, told the annual meeting of shareholders today.

30 Jan 2010

New vaccine effective in preventing TB in HIV patients

Investigators from Dartmouth Medical School (DMS) have reported results of a clinical trial showing that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection.

30 Jan 2010

Prime Therapeutics receives full accreditation from URAC Accreditation Committee for PrimeMail

Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, announced today that it has received full accreditation from the URAC Accreditation Committee for its mail-service pharmacy, PrimeMail®.

30 Jan 2010

PROLOR Biotech reports the EC approval of Merck's ELONVA

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today noted the European Commission (EC) approval of Merck & Co., Inc.'s ELONVA®, a long-acting CTP-modified version of the fertility drug follicle stimulating hormone (FSH).

30 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

Hormones & Cancer: A new journal from The Endocrine Society

Today, The Endocrine Society unveiled its newest journal, Hormones & Cancer. This bi-monthly journal will include research articles covering all aspects of hormone action on cancer causation, progression, dependence, prevention, resistance and treatment.

29 Jan 2010

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.

29 Jan 2010

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.

29 Jan 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA’s pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyra™.

29 Jan 2010

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Baxter International reports net income of $572M for the fourth-quarter of 2009

Baxter International Inc. today reported strong performance for the fourth quarter of 2009, and provided its financial outlook for the first quarter and full-year 2010.

From Baxter International Inc. 28 Jan 2010

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara’s board of directors.

28 Jan 2010

New insight into reprogramming of cells

A discovery by Babraham scientists brings new insight into how cells are reprogrammed and a greater understanding of how the environment, or factors like nutritional signals, can interact with our genes to affect health. As an embryo develops, cells acquire a particular fate, for example becoming a nerve or skin cell. The findings, reported online in the journal Nature, pinpoint a protein called AID as being important for complete cellular reprogramming in mammals.

28 Jan 2010

Onset Therapeutics expands its sales force to create nationwide presence

Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company’s recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas.

28 Jan 2010

Therapeutics News and Research

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Researchers identify antiviral small molecule that is effective against numerous viruses

Denim blue jeans ribbon campaign: an initiative to raise awareness about children with rare diseases

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Enzo Biochem generating more than $100M in revenues annually

New vaccine effective in preventing TB in HIV patients

Prime Therapeutics receives full accreditation from URAC Accreditation Committee for PrimeMail

PROLOR Biotech reports the EC approval of Merck's ELONVA

Global market for oncology drugs is forecast to reach $80 billion by 2050

Hormones & Cancer: A new journal from The Endocrine Society

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Baxter International reports net income of $572M for the fourth-quarter of 2009

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

New insight into reprogramming of cells

Onset Therapeutics expands its sales force to create nationwide presence

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News